Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis

Background Pulmonary hypertension (PH)-targeted therapy in the setting of pulmonary fibrosis (PF) is controversial; the main clinical concern is worsening of systemic hypoxaemia. We sought to determine the effects of gentle initiation and chronic administration of parenteral treprostinil on right heart function in patients with PF associated with an advanced PH phenotype. Methods Open-label, prospective analysis of patients with PF-PH referred for lung transplantation (LT). Advanced PH was defined as mean pulmonary artery pressure (mPAP) ≥35 mm Hg. We compared haemodynamics, Doppler echocardiography (DE), oxygenation, dyspnoea and quality of life indices, and 6 min walk distance (6MWD) before and 12 weeks after parenteral treprostinil. Results 15 patients were recruited in the study. After therapy, there were significant improvements in right heart haemodynamics (right atrial pressure (9.5 ± 3.4 vs 6.0 ± 3.7); mPAP (47 ± 8 vs 38.9 ± 13.4); CI (2.3 ± 0.5 vs 2.7 ± 0.6); pulmonary vascular resistance (698 ± 278 vs 496 ± 229); transpulmonary gradient (34.7 ± 8.7 vs 28.5 ± 10.3); mvO2 (65 ± 7.2 vs 70.9 ± 7.4); and stroke volume index (29.2 ± 6.7 vs 33 ± 7.3)) and DE parameters reflecting right heart function (right ventricular (RV) end diastolic area (36.4 ± 5.2 vs 30.9 ± 8.2 cm2), left ventricular eccentricity index (1.7 ± 0.6 vs 1.3 ± 0.5), tricuspid annular planar systolic excursion (1.6 ± 0.5 vs 1.9 ± 0.2 cm)). These changes occurred without significant alteration in systemic oxygenation, heart rate, or mean systemic arterial pressure. In addition, improvements were seen in 6MWD (171 ± 93 vs 230 ± 114), 36-Item Short Form Health Survey Mental Component Summary aggregate (38 ± 11 vs 44.2 ± 10.7), University of California, San Diego Shortness of Breath Questionnaire (87 ± 17.1 vs 73.1 ± 21), and brain natriuretic peptide (558 ± 859 vs 228 ± 340). Conclusions PH-targeted therapy may improve right heart haemodynamics and echocardiographic function without affecting systemic oxygen saturation in an advanced PH phenotype associated with RV dysfunction in the setting of PF.

[1]  K. Anstrom,et al.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. , 2013, Chest.

[2]  G. Raghu,et al.  Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial , 2013, European Respiratory Journal.

[3]  Artemis-Ipf Investigators.  Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial , 2013 .

[4]  H. Collard,et al.  Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan , 2013, Annals of Internal Medicine.

[5]  M. Puhan,et al.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[6]  A. Günther,et al.  Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial , 2012, European Respiratory Journal.

[7]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[8]  A. Günther,et al.  Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. , 2011, International journal of cardiology.

[9]  M. Humbert,et al.  Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. , 2011, Arthritis and rheumatism.

[10]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[11]  K. Wasserman,et al.  Exercise capacity in idiopathic pulmonary fibrosis: The effect of pulmonary hypertension , 2011, Respirology.

[12]  J. Barberà,et al.  Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. , 2011, Journal of applied physiology.

[13]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[14]  M. Gatzoulis,et al.  The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease , 2010, Respirology.

[15]  M. Mathier,et al.  Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[17]  M. Fishbein,et al.  Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[19]  B. Schmidt,et al.  Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. , 2009, Respiratory medicine.

[20]  A. Mehta,et al.  Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. , 2008, Respiratory medicine.

[21]  L. Brodin,et al.  Ventilation–perfusion relationships in pulmonary arterial hypertension: Effect of intravenous and inhaled prostacyclin treatment , 2007, Respiratory Physiology & Neurobiology.

[22]  T. Abraham,et al.  Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[23]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[24]  W. Seeger,et al.  Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[25]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[26]  R. Rodríguez-Roisín,et al.  Effect of pulmonary hypertension on gas exchange. , 1993, The European respiratory journal.

[27]  J. Roca,et al.  Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. , 1991, The American review of respiratory disease.

[28]  J. S. Bower,et al.  Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. , 1984, The American review of respiratory disease.

[29]  P. Wagner.  Influence of mixed venous PO2 on diffusion of O2 across the pulmonary blood:gas barrier. , 1982, Clinical physiology.

[30]  J. S. Bower,et al.  Pulmonary vascular tone improves VA/Q matching in obliterative pulmonary hypertension. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.

[31]  J. S. Bower,et al.  Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. , 1979, The Journal of clinical investigation.

[32]  J. Lynch,et al.  Influence of cardiac output on intrapulmonary shunt. , 1979, Journal of applied physiology: respiratory, environmental and exercise physiology.